Investigation of the Presence of Piriformis Syndrome Accompanying Lumbar Radiculopathy
Piriformis Syndrome, Lumbar Radiculopathy
About this trial
This is an interventional diagnostic trial for Piriformis Syndrome focused on measuring Piriformis Syndrome, Lumbar Radiculopathy, Ultrasonography, Diagnostic Injection
Eligibility Criteria
Inclusion Criteria:
- Aged over 18 years
- Having clinical symptoms and signs of L4/L5/S1 radiculopathy which may be supported by imaging and/or electrodiagnostic evaluation
- Having tenderness at the piriformis muscle
Exclusion Criteria:
- Injection history at the lumbar, hip, gluteal region in the last 6 months
- Operation history at the lumbar and/ or hip region
- History of inflammatory rheumatic disease
- History of infectious disease
- History of bleeding disorder
- History of anticoagulation use
- Uncontrolled diabetes mellitus or hypertension
- History of neurological disease
- Being in gestational or lactational period
- Noncompensated chronic heart/liver/renal deficiency, or vascular/tumoral disease
- Active psychiatric disease
- History of allergic reaction to the substance to be applied as local anesthetic
Sites / Locations
- Istanbul University-Cerrahpasa
Arms of the Study
Arm 1
Experimental
Piriformis syndrome with lumbar radiculopathy (PSWLR)
All patients (n=40) will be evaluated with detailed physical examination and special clinical tests for both lumbar radiculopathy and piriformis syndrome. If patients have lumbar magnetic resonance imaging or electromyography results, they will be recorded to confirm the diagnosis of lumbar radiculopathy. The patients who have the final diagnosis of lumbar radiculopathy and prediagnosis of piriformis syndrome will be evaluated for the pain scores (pain at resting, sitting, standing, lying, at night and during activity) using numeric rating scale. Then, an ultrasound guided piriformis muscle injection will be performed. The patients will be kept under observation for 30 minutes afterwards and the percentage of their pain relief will be recorded. The patients whose pain resolves at least 50% from the baseline after the injection will be diagnosed as piriformis syndrome and will be reevaluated one week and one month after the injection and the changes in the pain scores will be recorded.